RL
Therapeutic Areas
Gyre Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Hydronidone (F351) | MASH-associated Liver Fibrosis | Phase 2b |
| Pirfenidone | Idiopathic Pulmonary Fibrosis | Marketed |
| F573 | Acute-on-Chronic Liver Failure | Not Specified |
| F528 | Chronic Obstructive Pulmonary Disease | Not Specified |
| F230 | Pulmonary Arterial Hypertension | Not Specified |
Leadership Team at Gyre Therapeutics
PZ
Ping Zhang
Executive Chairman, Interim Chief Executive Officer
SM
Songjiang Ma
President, Board Member
RC
Ruoyu Chen
Chief Financial Officer
WY
Weiguo Ye
Chief Operating Officer
HY
Han Ying
Senior Vice President, Science
GG
Gordon G. Carmichael
Board Member
TE
Thomas Eastling
Board Member, CFO of Cullgen Inc.
DM
David M. Epstein
Board Member
RP
Renate Parry
Board Member
DW
Dan Weng
Board Member